US regulatory status: approved.
pharma · Melanoma · Alcohol Use Disorder · ADIL
ADIAL PHARMACEUTICALS
ADIAL PHARMACEUTICALS, INC.
ADIAL PHARMACEUTICALS drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CHARLOTTESVILLE, VA, ES HQ
2021 Founded
16 Employees
Public company Type
ADIL · NYSE Ticker
Company details
- Status
- Public
- HQ
- CHARLOTTESVILLE, VA, ES
- Founded
- 2021
- Employees
- 16
- Programs
- 6
- Drugs
- 9
- Patents
- 1
ADIAL PHARMACEUTICALS pipeline
Portfolio lens on 9 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ADIAL PHARMACEUTICALS drug portfolio — 9 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in ADIAL PHARMACEUTICALS's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
axitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
- Target
- Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
- Mechanism
- Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
-
US regulatory status: approved. Molecular target: Histamine H2 receptor.
- Target
- Histamine H2 receptor
- Mechanism
- Histamine H2 receptor antagonist
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
Development asset linked to ADIAL PHARMACEUTICALS in public FDA and regional records.
-
trametinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase; MEK1/2.
- Target
- Dual specificity mitogen-activated protein kinase kinase; MEK1/2
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor